Global Cancer Biological Therapy Market 2021

January 2022 | 17 pages | ID: GED2E3596475EN
StrategyHelix Inc

Abstracts

Biological therapy, also called immunotherapy, biological response modifier therapy, or biotherapy, uses the body's immune system to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Biological therapy for cancer is used in the treatment of many types of cancer to prevent or slow tumor growth and to prevent the spread of cancer. The global cancer biological therapy market is poised to grow by US$ 37,452 million during 2021-2027, progressing at a CAGR of 6.8% during the forecast period, according to data and analytics company StrategyHelix. Rising geriatric population, rising incidence of cancer, favorable government regulations and market initiatives, increasing research & development activities are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for cancer biological therapy. The global cancer biological therapy market is segmented on the basis of product, and region. By product, the global cancer biological therapy market has been segmented into monoclonal antibodies, vaccines, CAR T-cell therapy. The monoclonal antibodies segment was the largest contributor to the global cancer biological therapy market in 2020. Geographically, the global cancer biological therapy market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global cancer biological therapy market is highly competitive. The report also includes the profiles of leading companies such as Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck & Co. Inc., Novartis International AG, Pfizer Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cancer biological therapy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope
Product: monoclonal antibodies, vaccines, CAR T-cell therapy
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global cancer biological therapy market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. CANCER BIOLOGICAL THERAPY MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Monoclonal antibodies
Vaccines
CAR T-cell therapy

PART 4. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 5. KEY COMPANIES

Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genmab A/S
Gilead Sciences, Inc.
GlaxoSmithKline plc (GSK)
Janssen Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
About StrategyHelix
Disclaimer